Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 1Dermatologic 1Breast 1

Conditions

Fallopian Tube Neoplasms 3Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Neoplasms 1Melanoma 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

pembrolizumab 20Nivolumab 10Cyclophosphamide 10atezolizumab 6Specimen Handling 6fludarabine 5Magnetic Resonance Spectroscopy 5cabozantinib 4Ipilimumab 4Bevacizumab 4lenvatinib 3X-Rays 3Trastuzumab 3Paclitaxel 3Oxaliplatin 3Immunoglobulin G 3Fluorodeoxyglucose F18 3ulixertinib 2sargramostim 2poly ICLC 2epacadostat 2enzalutamide 2durvalumab 2cemiplimab 2budigalimab 2avelumab 2aldesleukin 2aflibercept 2Sirolimus 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Propranolol × Gynecologic × Clear all
NCT02013492 2022-12-06

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
1 enrolled
BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Hepatocellular, Melanoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡